Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 11/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951983 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3P2RX7KDM1A | |
| SCHEMBL950613 | 0.86 | BCHE (0.52) | SLC6A2SLC6A4SLC6A3KDM1AMAPT | |
| SCHEMBL950614 | 0.86 | BCHE (0.52) | SLC6A2SLC6A4SLC6A3KDM1AMAPT | |
| Hydrochloric Acid SCHEMBL950622 | 0.84 | BCHE (0.51) | SLC6A2SLC6A4SLC6A3KDM1AMAPT | |
| Hydrochloric Acid SCHEMBL951684 | 0.84 | BCHE (0.51) | SLC6A2SLC6A4SLC6A3KDM1AMAPT | |
| SCHEMBL696317 | 0.84 | BCHE (0.50) | P2RX7MAPTBCHEACHEBACE1 | |
| SCHEMBL5793320 | 0.83 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3P2RX7KDM1A | |
| SCHEMBL950740 | 0.81 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3P2RX7KDM1A | |
| SCHEMBL950739 | 0.81 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3P2RX7KDM1A | |
| SCHEMBL8268060 | 0.81 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KDM1ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868014-B2 | 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists | ELI LILLY AND COMPANY (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1805165-B1 | 1-(HETERO)ARYL-3-AMINO-PYRROLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | ELI LILLY AND COMPANY (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | GRM3, GRM1, GRIA3 | SLC6A2 1059/4885SLC6A4 437/4885SLC6A3 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.